ConvaTec Group stock (GB00BD3VFW73): dividend lift and guidance raise put medtech specialist in focus

ConvaTec Group has raised its dividend and tightened guidance after posting solid 2024 results and a confident 2025 outlook. The wound and ostomy care specialist is drawing fresh attention from income-focused investors and medtech watchers.

ConvaTec Group has moved back into the spotlight after publishing its full-year 2024 results in March 2025, including a higher final dividend and a reiterated ambition to lift margins over the medium term, according to a results release from the company dated 03/05/2025ConvaTec results release as of 03/05/2025. The medtech manufacturer, known for ostomy and advanced wound care products, also presented an encouraging outlook for 2025 with continued organic revenue growth and operating leverage, which kept the stock on the radar of European and US healthcare investors, as reported by Reuters in early March 2025Reuters as of 03/05/2025.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ConvaTec
• Sector/industry: Medical technology, wound and ostomy care
• Headquarters/country: Reading, United Kingdom
• Core markets: Europe and North America with global presence
• Key revenue drivers: Ostomy care, advanced wound care, continence and critical care, infusion care
• Home exchange/listing venue: London Stock Exchange (ticker: CTEC)
• Trading currency: GBP

ConvaTec Group: core business model

ConvaTec Group focuses on medical devices used primarily in chronic care settings, with a particular emphasis on ostomy products and advanced wound dressings. The company generates a significant share of its revenue from long-term recurring demand, as patients rely on ostomy pouches, wound dressings and continence management solutions over extended periods. This recurring profile gives the business a relatively defensive character, especially compared with more cyclical parts of the healthcare equipment sector.

Beyond ostomy and wound care, ConvaTec operates in continence and critical care as well as infusion care. In continence and critical care, the company supplies urine management and intensive care products used in hospitals and homecare environments. The infusion care unit specializes in infusion sets and related technologies, which are important, among other indications, for insulin pump therapy in diabetes management. This diversification across chronic therapies helps balance the portfolio and reduces reliance on a single product line.

ConvaTec distributes its products through a mix of direct sales, distributors and partnerships with healthcare providers, payers and pharmacies. Reimbursement regimes in the US, Germany and other European markets are central to demand, as they determine patient access and pricing. The business model benefits from demographic trends such as aging populations and rising incidence of chronic diseases, which typically support steady volume growth over time, even though pricing pressure from payers and procurement bodies remains a structural challenge.

Main revenue and product drivers for ConvaTec Group

Ostomy care remains one of the largest and most profitable segments for ConvaTec Group. The company offers ostomy solutions under brands that focus on discretion, skin protection and ease of use for patients living with a stoma after surgeries for colorectal cancer or inflammatory bowel disease. Product innovation in areas such as adhesive technology and comfort features helps the company defend and expand its share in a concentrated but competitive global market.

Advanced wound care is another key revenue pillar, targeting chronic wounds such as diabetic foot ulcers and venous leg ulcers. ConvaTec provides foam dressings, antimicrobial dressings and negative pressure therapies, aiming to support healing while lowering treatment costs for healthcare systems. The prevalence of diabetes and vascular disease has made chronic wound care a growing area, and the company continues to invest in new formulations and application systems to address clinical needs in hospitals and outpatient settings.

Infusion care adds an important technological angle to the portfolio, especially through infusion sets used in insulin pump therapy and other drug delivery applications. This segment is exposed to the broader diabetes technology ecosystem, where demand is influenced by pump manufacturers, patient adoption of insulin pumps and reimbursement decisions. In continence and critical care, ConvaTec supplies catheters, urine collection systems and other devices used mainly in acute care institutions, which tend to be sensitive to procurement cycles but provide consistent baseline demand.

Why ConvaTec Group matters for US investors

Although ConvaTec Group is listed in London and headquartered in the United Kingdom, the company has meaningful exposure to the US healthcare market through sales of ostomy, wound care and infusion products. US reimbursement frameworks and hospital procurement decisions therefore influence the company’s global growth trajectory. For US-based investors, the stock offers a way to gain exposure to chronic care medtech trends outside the domestic equity market while still being linked to familiar therapeutic areas such as diabetes care and advanced wound management.

Currency effects are an additional consideration for US investors because ConvaTec reports in US dollars but trades in British pounds on the London Stock Exchange. Movements in GBP/USD can affect the translated value of any investment and may also influence reported results when revenues are generated in multiple currencies. Furthermore, the company’s interactions with US regulators, hospital systems and private payers can shape its product mix and pricing strategies, making developments in the US healthcare environment relevant even though ConvaTec is not listed on a US exchange.

Conclusion

ConvaTec Group combines a defensive chronic care portfolio with targeted growth initiatives in areas such as advanced wound care and infusion therapy. Its recent 2024 results and dividend increase underline management’s focus on cash generation and shareholder returns within a regulated medtech landscape. For investors in Germany and the US who track international healthcare equipment names, the stock represents an example of a mid-cap specialist balancing recurring demand against reimbursement pressure and competitive dynamics, without this article expressing any view on suitability for individual portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.